Omeros Corporation
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSeattle, WA
US patents97
SAM.gov UEIHM97JEC22LP2
CAGE code357C4
Incorporated inWA
LEI549300CJWLXX2MXVVV71
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
97 US patents granted 2002–2025, 28 of them in the five years to SEP 2025.
Pharmaceuticals 82Organic fine chemistry 7Biotechnology 4Measurement 3Medical technology 1
- Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndromeUS 12,351,648 · granted JUL 8, 2025
- MASP-2 inhibitors and methods of useUS 12,195,427 · granted JAN 14, 2025
- Monoclonal antibodies, compositions and methods for detecting complement factor DUS 12,129,290 · granted OCT 29, 2024
- MASP-2 inhibitors and methods of useUS 12,110,288 · granted OCT 8, 2024
- Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereofUS 12,091,468 · granted SEP 17, 2024
Newest 5 shown · Granted to Omeros Corporation · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Omeros Corporation | Seattle | WA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.